New drug targets 'Undruggable' cancer mutations in first human test
Disease control
Terminated
This was an early safety study testing a new oral drug called MRTX0902, both alone and combined with another cancer drug (adagrasib), in people with advanced solid tumors that have specific genetic mutations in the KRAS pathway. The main goals were to find safe doses and see how …
Phase: PHASE1 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC